Nephrodite Wins FDA Breakthrough Device Designation for “Holly”
This investigational implantable, continuous dialysis device has completed its first large animal trials. The company plans to do Good Laboratory Practice studies followed by applying to regulators for first-in-human clinical trials.
Read the full article » | Posted 01-16-2026
Related Articles
- HollyTM Implantable Continuous Dialysis System Could be Ready for Human Trials Soon Posted 04-14-2026
- Xeltis is Trialing its Polymer-based Vascular Access Posted 03-12-2026
- New Bluetooth-enabled CAPD System Enhanced Patient Satisfaction Posted 03-12-2026
- Emerging Biomarker Research in PD Posted 03-12-2026

